Literature DB >> 12811813

Epstein-Barr virus: induction and control of cell transformation.

Riccardo Dolcetti1, Maria G Masucci.   

Abstract

Epstein-Barr virus (EBV), a ubiquitous human herpes virus, is associated with an increasing number of lymphoid and epithelial malignancies. The ability of the virus to establish life-long persistent infections and induce growth transformation is related to the function of a set of viral proteins that are variously expressed in both normal and malignant cells. Recent evidence indicates that these viral proteins are able to usurp cellular pathways that promote the cell growth and survival, while impairing anti-viral immune responses. Elucidation of the mechanisms by which EBV induces cell transformation and escapes host immune control provides the rational background for the design of new strategies of intervention for EBV-related malignancies. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811813     DOI: 10.1002/jcp.10263

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  19 in total

1.  Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?

Authors:  Riccardo Dolcetti; Antonino Carbone
Journal:  Infect Agent Cancer       Date:  2010-11-22       Impact factor: 2.965

2.  EPSTEIN -BARR VIRUS ASSOCIATION WITH MALIGNANT LYMPHOMA SUBGROUPS IN ZARIA, NIGERIA.

Authors:  Yawale Iliyasu; Leona W Ayers; Almustapha A Liman; Garba D Waziri; Sani M Shehu
Journal:  Niger J Surg Sci       Date:  2014

Review 3.  Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.

Authors:  Gyula Végso; Melinda Hajdu; Anna Sebestyén
Journal:  Pathol Oncol Res       Date:  2010-12-31       Impact factor: 3.201

4.  Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors.

Authors:  X Chen; S A Kamranvar; M G Masucci
Journal:  Oncogene       Date:  2015-11-23       Impact factor: 9.867

5.  Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes.

Authors:  Liliana Terrin; Jessica Dal Col; Enrica Rampazzo; Paola Zancai; Moreno Pedrotti; Grazia Ammirabile; Stefano Bergamin; Silvana Rizzo; Riccardo Dolcetti; Anita De Rossi
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

6.  The correlation between EBV viral load in the palatine tonsils of patients with recurrent tonsillitis and concurrent serum titers of VCA–IgG.

Authors:  Bora Dogan; Seyyal Rota; Levent Gurbuzler; Gulendam Bozdayi; Mustafa Nuri Ceyhan; Erdogan Inal
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01       Impact factor: 2.503

7.  Cross-linking of CD80 and CD86 Diminishes Expression of CD54 on EBV-transformed B Cells through Inactivation of RhoA and Ras.

Authors:  Ga Bin Park; Yeong Seok Kim; Hyunkeun Song; Seonghan Kim; Dong Man Park; Wang Jae Lee; Dae Young Hur
Journal:  Immune Netw       Date:  2011-12-31       Impact factor: 6.303

Review 8.  Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Authors:  Debora Martorelli; Elena Muraro; Anna Merlo; Riccardo Turrini; Damiana Antonia Faè; Antonio Rosato; Riccardo Dolcetti
Journal:  Clin Dev Immunol       Date:  2012-01-29

9.  Commentary: mechanistic considerations for associations between formaldehyde exposure and nasopharyngeal carcinoma.

Authors:  Chad M Thompson; Roland C Grafström
Journal:  Environ Health       Date:  2009-11-25       Impact factor: 5.984

Review 10.  Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.

Authors:  Dinesh Adhikary; Uta Behrends; Heike Boerschmann; Andrea Pfünder; Stefan Burdach; Andreas Moosmann; Klaus Witter; Georg W Bornkamm; Josef Mautner
Journal:  PLoS One       Date:  2007-07-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.